Medtronic has announced a strategic partnership with Hong Kong-based Cornerstone Robotics that includes an investment of approximately $700 million and rights to distribute Cornerstone's Sentire robotic surgery system in selected approved markets outside the United States. Sentire will complement Medtronic's Hugo robotic-assisted surgery platform, expanding the company's two-platform offering as it seeks to broaden access to minimally invasive procedures. Cornerstone developed Sentire through integrated in-house research and development and vertical integration. The system received approval from China's National Medical Products Administration in 2024, followed by a CE Mark in the European Union and approval from Singapore's Health Sciences Authority in May 2026 for general, gynecologic, thoracic and urologic minimally invasive procedures. Cornerstone has three global research and development centers, six business centers and a 30,000-square-meter manufacturing facility in China.